Full-Time

Registered Nurse

Interventional Care and Recovery

Deadline 8/25/27
Fraser Health

Fraser Health

10,001+ employees

Public health authority operating hospitals

Compensation Overview

CA$41.42 - CA$59.52/hr

Surrey, BC, Canada

In Person

Category
Medical, Clinical & Veterinary (1)
Required Skills
CPR
Vital Signs
Pharmacology

Get referred to Fraser Health

See people who can refer or advise you

Requirements
  • Current practicing registration as a Registered Nurse with the British Columbia College of Nurses and Midwives.
  • Completion of a recognized high acuity specialty nursing certificate and one year of recent related high acuity experience, or an equivalent combination of education, training and experience.
  • Current Cardiopulmonary Resuscitation certificate.
  • Demonstrated ability in nursing practice within a high acuity setting.
  • Demonstrated ability to assess patient responses and respond appropriately.
  • Demonstrated ability in the initiation and management of intravenous therapy and administration of intravenous medications.
  • Demonstrated ability to respond immediately and appropriately to emergencies.
  • Comprehensive knowledge of pharmacology and patient physiological reactions related to anesthesia and/or procedural sedation.
  • Demonstrated ability to plan and implement care plans.
  • Demonstrated ability to adjust to unexpected events, solve problems, set priorities and deal with conflict.
  • Demonstrated ability to work collaboratively as a member of an interdisciplinary team.
  • Demonstrated ability to communicate orally and in writing and deal effectively with patients and their families, coworkers, physicians, other health care staff and staff of external agencies.
  • Demonstrated ability to counsel and teach patients and their families.
  • Demonstrated ability to provide leadership through initiative and independence.
  • Demonstrated ability to model and mentor new staff and students.
  • Demonstrated skill in clinical techniques and the use of applicable equipment and supplies appropriate to an angiographic and/or interventional diagnostic imaging setting.
  • Demonstrated skill in cardiopulmonary resuscitation techniques.
  • Demonstrated skill in the use of cardiac monitoring equipment.
  • Demonstrated computer skills, including the ability to effectively use a computerized patient care information system.
  • Demonstrated physical ability to perform the duties of the position.
Responsibilities
  • Provide and coordinate pre- and post-procedure nursing care in the Interventional Radiology unit through assessment, planning, implementation and evaluation.
  • Provide individualized nursing care to patients with varying complexities before and after interventional procedures, ensuring comfort and safety.
  • Conduct health assessments, monitor vital signs and adjust care plans as needed.
  • Involve patients and families in care decisions and promptly respond to significant or life-threatening changes, evaluating the effectiveness of interventions.
  • Assist physicians during examinations in the pre- and post-Medical Imaging area.
  • Facilitate procedural sedation, general anesthesia where applicable, and airway management.
  • Monitor patient condition and ensure adherence to critical care safety protocols as needed.
  • Build therapeutic relationships with patients and families during pre-procedure preparation and offer emotional support throughout.
  • Verify patient identity, check consent, gather relevant information and provide clear explanations.
  • Advocate for informed decision-making and educate patients on procedures and post-care.
  • Anticipate, prepare for and respond to unexpected critical situations during or after procedures, such as cardiac arrest, by initiating cardiopulmonary resuscitation or administering appropriate medication.
  • Organize priorities in response to fluctuating workload volumes and patient treatment requirements in consultation with team members.
  • Assess patients for discharge in accordance with established discharge criteria.
  • Consult and collaborate with peers and other caregivers to identify and resolve patient and family care issues, ethical dilemmas, and care coordination and integration needs.
  • Act as a patient advocate by protecting and promoting patients' rights to autonomy, respect, privacy, dignity and access to information.
  • Document nursing observations, patient and family perspectives, and activities that support patient priorities.
  • Maintain complete and accurate computerized and paper records through data entry and documentation in accordance with established procedures and policies.
  • Use supplies and equipment according to safety and cost-effectiveness standards.
  • Maintain and troubleshoot patient-monitoring equipment and ensure proper handling and disposal of hazardous materials and sharps.
  • Follow Occupational Health and Safety guidelines.
  • Respond to incidents such as missing patients, injuries, emergencies, spills and disruptive behavior; notify appropriate staff and complete incident reports as required.
  • Participate in unit activities to improve care delivery and support evidence-based practice.
  • Promote quality improvement and report unsafe practices in line with professional and organizational standards.
  • Engage in evidence-based practice and research by reviewing relevant literature, applying approved findings in clinical care, and participating in approved nursing and interdisciplinary research projects.
  • Collaborate with team members to collect and summarize data, provide updates and evaluate outcomes.
  • Provide guidance on clinical and health-related tasks to designated caregivers.
  • Guide the clinical experience of assigned students and new staff and provide input to the Registered Nurse Supervisor or designated personnel on an individual's progress toward established nursing-care standards.
  • Maintain and update clinical knowledge within the area of practice.
  • Develop a professional development plan with designated personnel or the team and review progress to ensure goals are achieved within established time frames.
  • Perform other related duties as required.

Fraser Health is a health authority in British Columbia that provides a wide range of medical services to about 1.8 million people. It operates 12 hospitals, including major trauma centres, plus an outpatient care and surgery centre, and offers residential care, home health, public health, and mental health services. The organization employs over 40,000 staff, medical professionals, and volunteers who run clinics, care centres, and community programs. Its goal is to deliver accessible, high-quality care across the network while creating good workplaces for its employees and volunteers.

Company Size

10,001+

Company Stage

Grant

Total Funding

$20K

Headquarters

Surrey, Canada

Founded

2001

Get referred to Fraser Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The $18 million Mission Memorial ED expansion started construction in February 2026.
  • The Cloverdale UPCC opened January 28, 2026, with capacity for 64,000 annual visits.
  • Fraser Health won $1.3 million in March 2026 to expand Indigenous elder home care in Chilliwack.

What critics are saying

  • Mission Memorial ED faced repeated overnight shutdowns in May, June, and August 2026.
  • Physician staffing gaps still force service interruptions, signaling fragile emergency coverage across the network.
  • The Cloverdale hospital slipped from 2027 to 2030, weakening growth and credibility.

What makes Fraser Health unique

  • Fraser Health runs 12 hospitals and serves 1.8 million people across British Columbia.
  • Its Mission ED expansion adds 35% more space and reaches 41 care spaces by spring 2027.
  • Deloitte-backed AI scheduling models forecast patient surges and staffing demand across Fraser Health.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

11%

1 year growth

11%

2 year growth

11%
StockTitan
Mar 24th, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial.

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Arch Biopartners (OTCQB: ACHFF) announced a Clinical Trial Agreement with Fraser Health Authority to prepare Royal Columbian Hospital for recruitment in its Phase II trial of LSALT peptide for prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Royal Columbian Hospital is now the ninth global site activated and the fourth Canadian recruiting site, after Toronto General Hospital, St. Michael's Hospital, and University of Calgary. Positive. * Royal Columbian Hospital received final Research Ethics Board and operational approvals * Royal Columbian Hospital became the 9th global site activated in the Phase II CS-AKI trial * 4 Canadian sites are actively recruiting patients (Toronto General, St. Michael's, Calgary, RCH) Negative. 03/24/2026 - 09:13 AM TORONTO, March 24, 2026 (GLOBE NEWSWIRE) - Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA") with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada. Toronto General Hospital, part of University Health Network, St. Michael's Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: * LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. * Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. * CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide[1]. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. For more details about the Company's science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news. The Company has 66,933,289 common shares outstanding. | Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | / | | / | / | Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company's future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in the Company's most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company's most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedarplus.ca. References: * Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext The scientific and medical content of this release has been reviewed and approved by the Company's Chief Science Officer. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Faq. What does the Clinical Trial Agreement with Fraser Health mean for Arch Biopartners (ACHFF)? It enables Royal Columbian Hospital to prepare for patient recruitment in the Phase II CS-AKI trial. According to the company, RCH now has final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health, supporting site activation. How many sites are active in Arch Biopartners' (ACHFF) Phase II LSALT CS-AKI trial after Royal Columbian Hospital activation? Royal Columbian Hospital is the ninth site activated globally in the study. According to the company, RCH is also the fourth site in Canada to reach activation and prepare for recruitment. Which Canadian hospitals are currently recruiting for Arch Biopartners' (ACHFF) Phase II CS-AKI trial? Toronto General Hospital, St. Michael's Hospital, University of Calgary, and now Royal Columbian Hospital are recruiting. According to the company, those four Canadian centres are actively enrolling new patients into the trial. What approvals did Royal Columbian Hospital receive to start recruitment for the ACHFF Phase II trial? RCH received final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health. According to the company, these approvals complete site readiness for recruitment and study start-up activities. Will Arch Biopartners (ACHFF) add more sites in Canada and the US for the Phase II CS-AKI trial? The company is progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. According to the company, those discussions aim to expand site activation beyond the current nine global sites.

Black Press Media
Mar 14th, 2026
$1.3M funding will help more Indigenous elders in Chilliwack with at-home care

$1.3M funding will help more Indigenous elders in Chilliwack with at-home care. Published 8:45 am Saturday, March 14, 2026 An at-home program that offers care to Indigenous elders in the Fraser Valley will be expanding, with the main focus on Chilliwack, thanks to $1.3 million in new funding. The Indigenous Caregiver Support Model (ICSM) is a home-based program that supports elders with "complex needs to age safely at home and in their community," according to a Fraser Health press release. It is one of five programs in B.C. benefitting from a total of $6.3 million in funding from Health Research BC over the next three years. The funding will advance research to help B.C. seniors age comfortably in their own home. The ICSM program was launched in 2023 as a pilot project and has supported 33 elders and their caregivers in the Eastern Fraser Valley, including Chilliwack. Its aim is to reduce caregiver strain and improve elder wellbeing by providing culturally safe, coordinated in-home support, training, and financial assistance for Indigenous families caring for elders. It is co-designed by Fraser Health Indigenous Health, Stó:lō Service Agency, First Nations Health Authority, and Métis Nation British Columbia. "This model is an example of what is possible when care is built on relationships, trust and community," said Amanda LaBoucane, interim vice president, Indigenous Health and Cultural Safety. "Many elders and caregivers in the Chilliwack area have experienced firsthand the impacts of residential schools and the child welfare system. By strengthening caregiver capacity and confidence while bridging into integrated clinical care teams run by and for Indigenous people, we see improved health and wellness and stronger relationships within and between communities." The program is currently operating in the Fraser Valley, including Chilliwack, but the expansion will focus on urban Chilliwack as that is an identified need, said Carrie Stefanson with Fraser Health. Caregivers receive skills training and an honorarium to help reduce the economic strain of caregiving, while elders receive regular home visits from Indigenous-led clinical teams who provide culturally safe, relationship-based care, rooted in trust, kindness and respect, according to a Fraser Health.

Fraser Health
Sep 12th, 2024
Leveraging artificial intelligence to assist with scheduling

Fraser Health has partnered with Deloitte Canada to develop and launch scheduling tools that leverage artificial intelligence (AI) and machine-learning solutions to accurately forecast the waves in demand Fraserhealth see in the health system.

Government of British Columbia
Aug 22nd, 2024
Permanent supportive, complex-care homes open in Fraser Valley

For people not already connected to services, Fraser Health will work in partnership with Coast Mental Health to provide on-site clinical supports, including services from a psychiatric nurse, community nurse, licensed practical nurse, social worker and traditional wellness practitioners.

Daily Hive
Sep 12th, 2023
Construction begins on Surrey's new $2.9 billion Cloverdale hospital

Through a procurement process, Fraser Health has selected Ellis-Don Design Build to design and build the new facility through a design-build agreement.